DEVAL L PATRICK
CIK 1053466 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.27M
Companies
6
Total Filings
68
Lifetime Open-Market Net
-$6.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TWLO | Director | 18,718 | $197.35 | $3.69M | $0 | 22 | 2026-06-17 |
| TOST | Director | 45,815 | $32.27 | $1.48M | -$1.12M | 14 | 2026-06-16 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 13,743 | $44.96 | $617.9K | -$2.22M | 5 | 2024-06-07 |
| AMWL | Director | 8,895 | $10.75 | $95.6K | $150.0K | 6 | 2023-06-26 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 0 | $68.49 | $0 | -$2.83M | 16 | 2022-10-06 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | — | $18.07 | — | $0 | 1 | 2021-02-03 |
Recent Filings · Page 6 of 7
68 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-17 | TWLO | Grant (A) | +318 | $0 | EDGAR |
| 2021-06-17 | AMWL | Grant (A) | +14,440 | $0 | EDGAR |
| 2021-02-03 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-15 | TWLO | Grant (A) | +1,267 | $0 | EDGAR |
| 2020-11-04 | AMWL | Grant (A) | +15,498 | $0 | EDGAR |
| 2020-06-29 | Global Blood Therapeutics, Inc. (GBT) Delisted | Exer (M) | +2,400 | $0 | EDGAR |
| 2020-06-19 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-01 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-10 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | — | -$223.1K | EDGAR |
| 2019-06-20 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.